Source link : https://www.newshealth.biz/health-news/blincyto-picks-up-new-bcp-all-indication/
The US Food and Drug Administration approved blinatumomab (Blincyto — Amgen) as consolidation for CD19-positive, Philadelphia chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in both children and adults. Originally approved in 2014, the bispecific CD19-directed CD3 T-cell engager (BiTE) carries additional CD19-positive BCP-ALL indications for relapsed or refractory disease and disease in the first or […]
Author : News Health
Publish date : 2024-06-18 06:14:52
Copyright for syndicated content belongs to the linked Source.
Categories